Evaluation of Phentermine and Topiramate versus Phentermine/Topiramate Extended-Release in Obese Adults
Evaluation of Phentermine and Topiramate versus Phentermine/Topiramate Extended-Release in Obese Adults
复制标题
DOI：
10.1002/oby.20584
复制
发表时间：
2013-11-01
期刊：
影响因子：
6.9
通讯作者：
Gadde, Kishore M.
中科院分区：
文献类型：
--
作者：
Aronne, Louis J.;Wadden, Thomas A.;Gadde, Kishore M.
目的：一项为期28周的随机对照试验，比较了芬特明和托吡酯缓释剂的联合应用（PHEN/TPM ER）及其成分作为单一疗法和安慰剂用于肥胖成年人。设计和方法：受试者随机接受安慰剂、芬特明7.5 mg、芬特明15 mg、托吡酯ER 46 mg、托吡酯ER 92 mg、PHEN/TPM ER 7.5/46 mg、或PHEN/TPM ER 15/92 mg。所有受试者均接受生活方式干预咨询。结果：在第28周，PHEN/TPM ER 7.5/46（-8.5%）和15/92（-9.2%）与安慰剂相比（1.7%; P
Objective: A 28-week, randomized, controlled trial compared the combination of phentermine and topiramate extended-release (PHEN/TPM ER) with its components as monotherapies and with placebo in obese adults.Design and Methods: Subjects were randomized to placebo, phentermine 7.5 mg, phentermine 15 mg, topiramate ER 46 mg, topiramate ER 92 mg, PHEN/TPM ER 7.5/46 mg, or PHEN/TPM ER 15/92 mg. All subjects received lifestyle intervention counseling. Primary endpoints were percent weight loss (WL) and achievement of >= 5% WL.Results: At week 28, PHEN/TPM ER 7.5/46 (-8.5%) and 15/92 (-9.2%) achieved greater percentage WL versus placebo ( 1.7%; P